Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients

Giovanni Scambia, Maria Gabriella Ferrandina, Francesco Legge, Amelia Paglia, Marco D'Asta, Gilda Fuoco

Risultato della ricerca: Contributo in rivistaArticolo in rivista

32 Citazioni (Scopus)

Abstract

Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients.
Lingua originaleEnglish
pagine (da-a)214-214
Numero di pagine1
RivistaBMC Cancer
Volume11
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Adult
  • Aged
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin
  • Endostatins
  • Female
  • Humans
  • Middle Aged
  • Neovascularization, Pathologic
  • Ovarian Neoplasms
  • Pyrazoles
  • Quality of Life
  • Recurrence
  • Sulfonamides
  • Survival Analysis
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A

Fingerprint Entra nei temi di ricerca di 'Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients'. Insieme formano una fingerprint unica.

Cita questo